← Back to headlines
RBC Capital Raises Price Target on Neurocrine Biosciences (NBIX)
RBC Capital has raised its price target for Neurocrine Biosciences (NBIX), signaling a positive outlook for the biopharmaceutical company's stock.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
